| URL | https://www.americanpharmaceuticalreview.com/Speci |
| Source | American Pharmaceutical Review |
| Date Published | 10/20/2022 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Andelyn Biosciences |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Columbus |
| State(s) reshored to: | OH |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | genecell therapies, biopharmaceuticals |
| What domestic positive factors made reshoring more attractive? | Customer responsiveness improvement, Proximity to customers/market |